Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals

Read MoreHide Full Article

For Immediate Release

Chicago, IL – June 30, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intellia Therapeutics, Inc. (NTLA - Free Report) , Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , CRISPR Therapeutics AG (CRSP - Free Report) , Beam Therapeutics Inc. (BEAM - Free Report) and Vertex Pharmaceuticals Incorporated (VRTX - Free Report) .

Here are highlights from Tuesday’s Analyst Blog:

3 Biotech Stocks Up on Intellia's CRISPR Study Data

The gene-editing field crossed a major milestone as Intellia Therapeutics announced data from the first-ever human study evaluating an in vivo CRISPR-based gene editing therapy candidate. Last weekend, Intellia and its partner, Regeneron announced interim data from a phase I study evaluating their in vivo CRISPR genome editing candidate, NTLA-2001, that supported potential of this singe-dose novel treatment option for patients with transthyretin (ATTR) amyloidosis, a genetic disease.

Interim data from the first six ATTRv-PN patients from the phase I study showed that treatment with a single dose of NTLA-2001 (0.3 mg/kg) led to a mean reduction of 87% in serum TTR levels, with a maximum 96% serum TTR reduction by day 28, with dose-dependent response. Usually, the standard of care for ATTRv-PN generates TTR reductions of approximately 80%.

Please note that CRISPR is an acronym for Clustered Regularly Interspaced Short Palindromic Repeats. The technology can selectively delete, modify or correct a disease-causing abnormality in a specific deoxyribonucleic acid segment.

With the availability of the interim data on NTLA-2001, the scientific community achieved a new feat of precisely editing target cells within the body to treat a genetic disease with a single intravenous infusion of CRISPR. Genomic editing to repair defective genetic material that causes diseases using CRISPR/Cas9 gene editing technology is probably one of the most promising and exciting healthcare innovations seen in decades. The technology has the potential to change how diseases, especially those caused by genetic mutations, are treated and may provide a cure for these difficult-to-treat diseases.

In fact, companies that have been developing CRISPR gene editing therapies saw their shares soar as Intellia's NTLA-2001 demonstrated its potential. Apart from Intellia, which surged more than 50% on Jun 28 following the news, CRISPR Therapeutics was up 6.4% and Beam Therapeutics was up 16%. This correlated move among biotech happens often as investors view promising news for one company as potentially good news for other companies with similar products, especially novel ones in development.

CRISPR Therapeutics

The company is developing its lead pipeline candidate, CTX001, in collaboration with Vertex Pharmaceuticals in mid-stage studies as a potential treatment for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD). The gene-editing therapy candidate previously demonstrated a consistent and sustained response to treatment in the given patient population in an ongoing phase I/II study.

Meanwhile, CRISPR Therapeutics is actively seeking collaborations and leveraging its CRISPR/Cas9 gene-editing platform to make therapies for hemoglobinopathies, cancer, diabetes and other diseases.

CRISPR Therapeutics shares have risen 93.9% in the past year against the industry's decrease of 1.4%.

CRISPR Therapeutics has a Zacks Rank #3 (Hold).

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Editas Medicine

The company's lead pipeline candidate is EDIT-101, which employs CRISPR gene editing to treat LCA10 — a rare genetic illness that causes blindness. Editas is currently enrolling in the first pediatric cohort of the phase I/II BRILLIANCE study, which is evaluating EDIT-101 for LCA10. Editas is also pursuing the development of CRISPR candidates for eye diseases other than LCA10 including Usher Syndrome type 2A and recurrent ocular Herpes Simplex Virus type 1.

It is also designing novel medicines for non-malignant hematologic diseases, such as SCD and beta-thalassemia.

In the past year, shares of Editas have gained 41.6% compared with the industry's 1.4% increase.

The company currently carries a Zacks Rank of 4 (Sell).

Beam Therapeutics

The company's stock has surged 235.2% so far this year against a decrease of 1.4% for the industry.

The company has two pre-clinical gene editing candidates, BEAM-101 and BEAM-102, in its pipeline that are being developed as potential treatment for SCD. The company plans to file an investigational new drug application to the FDA seeking approval to start a clinical study on BEAM-101 in the second half of 2021.

Beam Therapeutics carries a Zacks Rank #4.

+1,500% Growth: One of 2021's Most Exciting Investment Opportunities

In addition to the stocks you read about above, would you like to see Zacks' top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.

Zacks has released a special report to help you capitalize on the Internet of Things's exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.

Click here to download this report FREE >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

https://www.zacks.com                                          

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.